Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NMSCs, ovarian ...

For Novartis, oncology is a key strategic area, but it is still short of dominating the field. It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

Sigma Planning Corp cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 19.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,218 shares of the company’s stock after ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Legos joins the Big Pharma from Novartis, where he served as executive vice president and global head of oncology and hematology development. Before that, Legos held various leadership roles at GSK.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...